Using 68Ga-FAPI PET/CT to visualize malignant tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the use of a novel imaging agent, 68Ga-FAPI, in conjunction with PET/CT scans to enhance the visualization of malignant tumors. The study aims to evaluate the effectiveness of this molecular imaging technique in detecting and characterizing tumors, particularly in gastrointestinal cancers. By targeting fibroblast activation protein (FAP), which is overexpressed in cancer-associated fibroblasts, the trial seeks to provide more accurate diagnostic information compared to traditional imaging methods. The research will involve patients with suspected or confirmed malignant tumors to assess the advantages of this approach over existing imaging modalities.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Volunteering to participate in clinical trial and sign an informed consent form Patients with suspected or confirmed malignant tumor

Exclusion Criteria:

Female patients plan to become pregnant within 6 months Pregnant and lactating women Patients are allergic to multiple drugs including test drug Patients have participated in other clinical trials in the past one month

Where it's running

• Zhongnan Hospital of Wuhan University
  Wuhan, Hubei, China Recruiting

Study contacts

• Principal investigator: Yong He, MD, PhD — Zhongnan Hospital
• Study coordinator: Yong He, MD, PhD
• Email: vincentheyong@163.com
• Phone: +86-27-67812698

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PET scan targeting CDH3 for lung tumors

  This will test whether a new PET imaging agent called 68Ga-TOI-1 that targets CDH3 can better detect and stage lung tumors and help tell malignant from benign pulmonary nodules in adults with suspected or confirmed non-small cell lung cancer.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07487883

• Targeting Integrin αvβ6 for PET Imaging in Cancer

  This study is testing a new imaging tool to see if it can help doctors better diagnose and stage certain cancers, like lung and breast cancer, by using a special scan that targets a specific protein found in tumors.

  Recruiting Zhongnan Hospital · Wuhan, Hubei · NCT05835570

• Omni 128 cm PET/CT imaging system: comparing new scanner with standard PET/CT

  This study tests a new Omni 128 cm PET/CT scanner by having adults with a planned clinical PET/CT also undergo an extra research scan to compare image quality.

  Recruiting GE Healthcare · Stanford, California · NCT07857161

• MK-2010 with Sac-TMT in advanced solid tumors

  This study tests MK-2010 combined with sacituzumab tirumotecan (sac-TMT) to see if it can help people with advanced solid tumors.

  Recruiting at 4 sites Phase 2 Merck Sharp & Dohme LLC · San Antonio, Texas and 3 other locations · NCT07785609

• Belzutifan in adolescents with solid tumors

  This study tests belzutifan in teenagers whose solid tumors can't be removed by surgery or have spread.

  Recruiting at 10 sites Phase 2 Merck Sharp & Dohme LLC · Iowa City, Iowa and 9 other locations · NCT07700758

• DLL3-targeted PET/CT for small cell lung cancer

  This study tests whether DLL3-targeted PET/CT can better detect lesions in people with suspected or confirmed small cell lung cancer compared with standard imaging.

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07677787

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.